EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transcranial photobiomodulation for reducing symptoms of autism spectrum disorder and modulating brain electrophysiology in children aged 2–7: an open label study

Yuli Fradkin, Joaquin A Anguera, Alexander J Simon, Luis De Taboada, Eugenia Steingold

Frontiers in Child and Adolescent Psychiatry · 29.01.2025 · 4

DOI: 10.3389/frcha.2025.1477839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Child and Adolescent Psychiatry, online erschienen am 29.01.2025. Verfasst von Yuli Fradkin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Small pilot studies have indicated that transcranial photobiomodulation (tPBM) may help alleviate symptoms of neurological conditions like depression, traumatic brain injury and Autism Spectrum Disorder (ASD).

Objective

To examine the effect of tPBM on the behavioral symptoms of ASD and brain electrophysiology in children aged 2–7.

Methods

We conducted an open label, one-arm study with 23 participants, aged 2–7, previously diagnosed with ASD. We delivered non-invasively to all participants pulses of near-infrared light (wavelength 850 nm, pulse 40 Hz) to cortical nodes of Default Mode Network, Broca and Wernicke areas, and occipital lobe of the brain, twice weekly for 10 weeks. The tPBM was delivered using an investigational medical device designed for this purpose. Changes in ASD symptoms were measured using pre- and post-intervention scores on the Childhood Autism Rating Scale (CARS-2, 2nd Edition). We collected electroencephalogram (EEG) data after each treatment session from all children who tolerated wearing the EEG cap to monitor changes in brain activity.

Results

The intervention resulted in a significant 7-point reduction in average CARS-2 scores ( t = 10.23, p < .0001), along with decreased delta power and increased gamma and beta power in EEG readings. The increase in gamma power was statistically significant [ t (14) = 2.30, p = 0.047]. Changes in EEG power were significantly correlated with the number of sessions (delta: r (192) = −0.18, p = .013; gamma: r (192) = .19, p = .007; beta: r (192) = .15, p = .04). Improvements in CARS-2 scores were negatively correlated with changes in delta and beta power (delta: r (15) = −.59, p = .020; beta: r (15) = −.54, p = .037). No moderate or severe side effects were reported.

Conclusion

This study supports the potential of tPBM as a safe and effective treatment for ASD, and it suggests that EEG measurements may serve as a useful biomarker for future research. Trial Registration https://clinicaltrials.gov/ct2/show/NCT04660552

Schlagwörter

Stichwörter der Autor:innen

ASDEEGautism spectrum disorderdelta powerpediatric neurologyphotobiomodulationtranscranial photobiomodulation

Autor:innen und Institutionen

  • Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, United States.
  • Director of Clinical Division, Neuroscape Associate Professor, Neurology and Psychiatry, Weill Institute for Neurosciences & Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, CA, Uni…
  • Interdepartmental Neuroscience Program, Yale University, New Haven, CT, United States.
  • JelikaLite Corp., New York, NY, United States.

Zitieren

APA

Fradkin, Y., Anguera, J. A., Simon, A. J., De Taboada, L., & Steingold, E. (2025). Transcranial photobiomodulation for reducing symptoms of autism spectrum disorder and modulating brain electrophysiology in children aged 2–7: an open label study. Frontiers in Child and Adolescent Psychiatry, 4. https://doi.org/10.3389/frcha.2025.1477839

Vancouver

Fradkin Y, Anguera JA, Simon AJ, De Taboada L, Steingold E. Transcranial photobiomodulation for reducing symptoms of autism spectrum disorder and modulating brain electrophysiology in children aged 2–7: an open label study. Frontiers in Child and Adolescent Psychiatry. 2025;4. doi:10.3389/frcha.2025.1477839

BibTeX
@article{Fradkin2025,
  author = {Fradkin, Yuli and Anguera, Joaquin A and Simon, Alexander J and De Taboada, Luis and Steingold, Eugenia},
  title = {Transcranial photobiomodulation for reducing symptoms of autism spectrum disorder and modulating brain electrophysiology in children aged 2–7: an open label study},
  journal = {Frontiers in Child and Adolescent Psychiatry},
  year = {2025},
  volume = {4},
  doi = {10.3389/frcha.2025.1477839}
}
Kostenlos starten →